NO20055445L - Anvendelse av en blanding for fremstilling av et medikament for perioperativt a hemme smerte, betennelse og/eller spasme, og en losning for perioperativt a hemme smerte, betennelse og/eller spasme - Google Patents
Anvendelse av en blanding for fremstilling av et medikament for perioperativt a hemme smerte, betennelse og/eller spasme, og en losning for perioperativt a hemme smerte, betennelse og/eller spasmeInfo
- Publication number
- NO20055445L NO20055445L NO20055445A NO20055445A NO20055445L NO 20055445 L NO20055445 L NO 20055445L NO 20055445 A NO20055445 A NO 20055445A NO 20055445 A NO20055445 A NO 20055445A NO 20055445 L NO20055445 L NO 20055445L
- Authority
- NO
- Norway
- Prior art keywords
- antagonists
- receptor
- spasm
- solution
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Det beskrives en anvendelse av en blanding i fremstillingen av et medikament for peri-operativt å hemme smerte og betennelse og/eller spasme ved en vaskulær struktur under en intravaskulær prosedyre, ved under prosedyren å tilføre blandingen lokalt til den vaskulære strukturen, eventuelt der medikamentet er, for kontinuerlig å skylle ut strukturen med løsningen under prosedyren, der blandingen omfatter en fortynnet løsning av et flertall av hemmende midler utvalgt fra smerte/ betennelseshemmende midler og spasmehemmende midler i en fysiologisk flytende bærer, der de ulike midler blir utvalgt fra en rekke klasser av midler som virker gjennom forskjellige molekylære mekanismer på ulike molekylære mål som medierer smerte og betennelse og/eller spasme, og der midlene kollektivt er effektive for å hemme smerte og betennelse og/eller spasme ved den vaskulære struktur, hvor hvert middel er inkludert i en konsentrasjon på ikke mer enn 1 00 000 nanomolar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35377594A | 1994-12-12 | 1994-12-12 | |
PCT/US1995/016028 WO1996019233A2 (en) | 1994-12-12 | 1995-12-12 | Irrigation solution and method for inhibition of pain, inflammation and spasm |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20055445L true NO20055445L (no) | 1997-08-07 |
Family
ID=23390519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055445A NO20055445L (no) | 1994-12-12 | 2005-11-17 | Anvendelse av en blanding for fremstilling av et medikament for perioperativt a hemme smerte, betennelse og/eller spasme, og en losning for perioperativt a hemme smerte, betennelse og/eller spasme |
Country Status (13)
Country | Link |
---|---|
US (6) | US5860950A (no) |
EP (3) | EP2301562B1 (no) |
JP (3) | JP2007031454A (no) |
CN (1) | CN1160115C (no) |
AT (2) | ATE300308T1 (no) |
CA (1) | CA2206119C (no) |
DE (1) | DE69534341T2 (no) |
ES (3) | ES2421306T3 (no) |
HK (1) | HK1008983A1 (no) |
MX (1) | MX9703988A (no) |
NO (1) | NO20055445L (no) |
RU (1) | RU2180852C2 (no) |
WO (1) | WO1996019233A2 (no) |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087479A (en) | 1993-09-17 | 2000-07-11 | Nitromed, Inc. | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US6057287A (en) * | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20040127884A1 (en) * | 1994-12-12 | 2004-07-01 | Omeros Corporation | Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
KR100517210B1 (ko) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US6413961B1 (en) | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
BR9509985A (pt) | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solução para irrigação e método para inibição de dor inflamação e esparmo |
KR100499190B1 (ko) * | 1996-03-29 | 2006-04-17 | 교와 핫꼬 고교 가부시끼가이샤 | 육모제 |
US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
ATE333879T1 (de) * | 1996-10-07 | 2006-08-15 | Merck Sharp & Dohme | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
AU750755B2 (en) * | 1997-09-26 | 2002-07-25 | Abbvie Deutschland Gmbh & Co Kg | Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
DE19743142A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
HU1500214D0 (hu) | 1997-12-22 | 2002-03-28 | Euro Celtique Sa | Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény |
JP2001526229A (ja) | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク,エス.エイ. | オピオイド投薬剤形の乱用を防止する方法 |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
US6183461B1 (en) | 1998-03-11 | 2001-02-06 | Situs Corporation | Method for delivering a medication |
US6136804A (en) | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
EP1067950B1 (en) * | 1998-04-10 | 2008-05-14 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
US6673832B1 (en) * | 1998-05-04 | 2004-01-06 | Gudarz Davar | Methods for identifying compounds for treating pain |
US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
EP1112070B1 (en) * | 1998-08-20 | 2004-05-12 | Smithkline Beecham Corporation | Novel substituted triazole compounds |
WO2000021564A1 (en) * | 1998-10-09 | 2000-04-20 | Schering Corporation | Composition and method for treating allergic diseases |
US7973068B2 (en) * | 1998-10-20 | 2011-07-05 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
EP1563838A3 (en) * | 1998-10-20 | 2009-11-04 | Omeros Corporation | Irrigation solution and method for inhibition of pain and inflammation |
ATE291907T1 (de) * | 1998-10-20 | 2005-04-15 | Omeros Corp | Spülende lösung und methoden zur hemmung von schmerzen und entzündungen |
US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
US20030087962A1 (en) * | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
ATE324901T1 (de) * | 1998-11-10 | 2006-06-15 | Univ Temple | Hemmung der angiogenese durch peptidanaloge der kininogen domäne 5mit hohem molekulargewicht |
WO2000048581A2 (en) | 1999-02-18 | 2000-08-24 | Novartis Ag | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
DE60023125T2 (de) | 1999-03-08 | 2006-06-22 | University Of Manitoba, Winnipeg | Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel |
US7091140B1 (en) | 1999-04-07 | 2006-08-15 | Polymer Group, Inc. | Hydroentanglement of continuous polymer filaments |
US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
US6139535A (en) * | 1999-05-27 | 2000-10-31 | Situs Corporation | Method and apparatus for placement and activation of a medical device within a body cavity |
US6489345B1 (en) | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
EP1872797A3 (en) * | 1999-08-24 | 2008-04-02 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
US6759410B1 (en) * | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
CA2396739A1 (en) | 1999-12-06 | 2001-06-14 | Krishna G. Peri | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
OA12215A (en) | 2000-02-08 | 2006-05-09 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
DE60110054T2 (de) | 2000-02-29 | 2006-03-09 | Medicure International Inc. | Cardioprotektive phosphonate |
AU784840B2 (en) | 2000-03-28 | 2006-07-06 | Medicure International Inc. | Treatment of cerebrovascular disease |
AU7007001A (en) | 2000-06-22 | 2002-01-02 | Nitromed Inc | Nitrosated and nitrosylated taxanes, compositions and methods of use |
WO2002004421A2 (en) | 2000-07-07 | 2002-01-17 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6743812B1 (en) * | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
CA2414941C (en) | 2000-08-11 | 2010-12-14 | David R. Whitlock | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
US7445619B2 (en) * | 2000-08-18 | 2008-11-04 | Map Technologies Llc | Devices for electrosurgery |
US7771422B2 (en) | 2002-06-06 | 2010-08-10 | Nuortho Surgical, Inc. | Methods and devices for electrosurgery |
US7819861B2 (en) * | 2001-05-26 | 2010-10-26 | Nuortho Surgical, Inc. | Methods for electrosurgical electrolysis |
US6902564B2 (en) * | 2001-08-15 | 2005-06-07 | Roy E. Morgan | Methods and devices for electrosurgery |
WO2002026020A2 (en) * | 2000-09-26 | 2002-04-04 | The Brigham And Women's Hospital, Inc. | Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
US7074961B2 (en) | 2000-09-26 | 2006-07-11 | The Brigham And Women's Hospital, Inc. | Antidepressants and their analogues as long-acting local anesthetics and analgesics |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
AU2002305123B2 (en) * | 2001-03-30 | 2006-10-05 | Philadelphia Health And Education Corporation | Immunomodulation and effect on cell processes relating to serotonin family receptors |
ES2361148T3 (es) | 2001-05-11 | 2011-06-14 | Endo Pharmaceuticals Inc. | Forma de dosificación de opioides de liberación controlada resistente al abuso. |
US7066932B1 (en) | 2001-05-26 | 2006-06-27 | Map Technologies Llc | Biologically enhanced irrigants |
ITMI20011308A1 (it) * | 2001-06-21 | 2002-12-21 | Nicox Sa | Farmaci per il dolore cronico |
DE60230632D1 (de) * | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | Pharmazeutische kombinationen von oxycodon und naloxon |
AU2002324624A1 (en) * | 2001-08-06 | 2003-02-24 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
IS7142A (is) | 2001-08-06 | 2004-02-05 | Euroceltique S.A. | Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi |
US8734441B2 (en) | 2001-08-15 | 2014-05-27 | Nuortho Surgical, Inc. | Interfacing media manipulation with non-ablation radiofrequency energy system and method |
US8591508B2 (en) * | 2001-08-15 | 2013-11-26 | Nuortho Surgical, Inc. | Electrosurgical plenum |
US8235979B2 (en) | 2001-08-15 | 2012-08-07 | Nuortho Surgical, Inc. | Interfacing media manipulation with non-ablation radiofrequency energy system and method |
JP2005505385A (ja) | 2001-10-12 | 2005-02-24 | アプライド メディカル リソーシーズ コーポレイション | 高流量低圧灌注システム |
EP1448152A4 (en) * | 2001-10-31 | 2006-06-07 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF PAINFUL DISORDERS USING 2047 |
ATE493126T1 (de) | 2001-11-01 | 2011-01-15 | Spectrum Pharmaceuticals Inc | Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs |
US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
US7973064B2 (en) * | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
WO2003057380A2 (en) * | 2002-01-11 | 2003-07-17 | Whitlock David R | Compositions including ammonia oxidizing bacteria and methods of using same |
US20030181426A1 (en) * | 2002-02-11 | 2003-09-25 | Eisenach James C. | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
EP2425823A1 (en) | 2002-04-05 | 2012-03-07 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
ES2709103T3 (es) * | 2002-08-28 | 2019-04-15 | Dyax Corp | Métodos para conservar órganos y tejidos |
EP1551372B8 (en) * | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sequestering subunit and related compositions and methods |
WO2004037235A2 (en) | 2002-10-24 | 2004-05-06 | The Board Of Trustees Of The University Of Illinois | Method and composition for preventing and treating solid tumors |
US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
DK1624936T3 (da) | 2003-05-16 | 2010-03-15 | Univ Laval | CNS-chloridmodulering og anvendelser deraf |
WO2005023189A2 (en) * | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
CA2539974A1 (en) * | 2003-09-26 | 2005-04-07 | David R. Whitlock | Methods of using ammonia oxidizing bacteria |
US7799832B2 (en) * | 2003-10-23 | 2010-09-21 | Valeant Pharmaceuticals North America | Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
US20070239107A1 (en) * | 2003-12-15 | 2007-10-11 | Jon Lundberg | Device and Method for Administering Therapeutic Agents |
CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α-2-δ配体的组合 |
EP1604666A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
EP1773370A1 (en) * | 2004-07-07 | 2007-04-18 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US7235530B2 (en) * | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
CA2585165A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
EP1702558A1 (en) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
JP5008206B2 (ja) * | 2005-05-20 | 2012-08-22 | オメロス コーポレイション | シクロオキシゲナーゼインヒビターおよびカルシウムチャネルアンタゴニストの組成物、ならびに泌尿器科の処置において使用するための方法 |
AU2006317440A1 (en) * | 2005-11-28 | 2007-05-31 | Medicure International Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
WO2007100718A2 (en) * | 2006-02-24 | 2007-09-07 | Denise Barbut | Neurotensin receptor agonists and opioid receptor agonists |
WO2007106746A2 (en) * | 2006-03-10 | 2007-09-20 | Dyax Corp. | Formulations for ecallantide |
US7960436B2 (en) * | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
US20080045534A1 (en) * | 2006-08-18 | 2008-02-21 | Valeant Pharmaceuticals North America | Derivatives of 1,3-diamino benzene as potassium channel modulators |
US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
SG174095A1 (en) * | 2006-08-23 | 2011-09-29 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
WO2008027839A1 (en) | 2006-08-31 | 2008-03-06 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
BRPI0719590A2 (pt) * | 2006-11-28 | 2014-01-21 | Valeant Pharmaceuticals Int | Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio |
US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
US7786146B2 (en) | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20100266645A1 (en) * | 2007-12-17 | 2010-10-21 | Alfred Liang | Pharmaceutical compositions |
EP2317991B1 (en) * | 2008-07-07 | 2017-05-03 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
AU2010203712A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
US9532827B2 (en) | 2009-06-17 | 2017-01-03 | Nuortho Surgical Inc. | Connection of a bipolar electrosurgical hand piece to a monopolar output of an electrosurgical generator |
RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
RU2597265C2 (ru) * | 2010-12-09 | 2016-09-10 | Радикал Терапьютикс Инк. | Многофункциональные производные нитроксида и их применение |
AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
US9408658B2 (en) | 2011-02-24 | 2016-08-09 | Nuortho Surgical, Inc. | System and method for a physiochemical scalpel to eliminate biologic tissue over-resection and induce tissue healing |
EP2739266B1 (en) * | 2011-08-04 | 2016-07-27 | Omeros Corporation | Stable anti-inflammatory solutions for injection |
US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
US9579142B1 (en) | 2012-12-13 | 2017-02-28 | Nuortho Surgical Inc. | Multi-function RF-probe with dual electrode positioning |
US11992485B2 (en) | 2013-07-22 | 2024-05-28 | Hutchison Health, Llc | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
US11992484B2 (en) | 2013-07-22 | 2024-05-28 | Hutchison Health, Llc | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
US11559521B2 (en) | 2013-07-22 | 2023-01-24 | William Bradley Worthington | Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief |
CN105517551A (zh) | 2013-07-23 | 2016-04-20 | 欧洲凯尔特公司 | 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合 |
KR101462474B1 (ko) * | 2013-10-30 | 2014-11-19 | 주식회사 큐리언트 | 질레우톤 크림 제형의 국소용 항염증 약학적 조성물 |
CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
KR20230165365A (ko) | 2014-04-15 | 2023-12-05 | 에이오바이오미 엘엘씨 | 암모니아-산화 니트로소모나스 유트로파 균주 d23 |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
TWI809304B (zh) | 2014-12-01 | 2023-07-21 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
CN105031381A (zh) * | 2015-09-08 | 2015-11-11 | 济南舜昊生物科技有限公司 | 一种用于孕妇口腔局部麻醉的药物及其制备方法 |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
AU2018297214B2 (en) | 2017-07-06 | 2022-09-01 | Caventure Drug Discovery, Inc. | A peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response |
CN110123833A (zh) * | 2019-05-31 | 2019-08-16 | 龚啸元 | 一种关节镜手术用灌流液及其制备方法 |
CN111000983A (zh) * | 2019-12-25 | 2020-04-14 | 长春生物制品研究所有限责任公司 | 一种新的重组人白细胞介素-1受体拮抗剂的药用用途 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443432A (en) * | 1981-10-05 | 1984-04-17 | Alcon Laboratories, Inc. | Ophthmalic irrigating solution |
DE3316510A1 (de) * | 1983-05-06 | 1984-11-08 | Bayer Ag | Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen |
US4640912A (en) * | 1983-06-09 | 1987-02-03 | Hausman Marvin S | Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans |
US4504493A (en) | 1983-07-15 | 1985-03-12 | University Of Southern California By G. June Marshall | Solution for surgical irrigation |
SU1337105A1 (ru) * | 1985-05-07 | 1987-09-15 | Киевский Научно-Исследовательский Институт Медицинских Проблем Физической Культуры | Способ лечени ожоговых ран |
US4696917A (en) * | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
US4637815A (en) * | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
US4872865A (en) * | 1985-10-09 | 1989-10-10 | Harrington Arthritis Research Center | Hypertonic solution for arthroscopic surgery |
FR2598081B1 (fr) * | 1986-04-30 | 1990-02-02 | Chauvin Blache Lab | Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue par un acide organique |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
JPS63115818A (ja) * | 1986-08-27 | 1988-05-20 | ジヨ−ジ・ア−ル・ケイリ−・ジュニア | 術後痛の消滅又は改善のための局所用組成物 |
US5272139A (en) * | 1986-08-27 | 1993-12-21 | Cary George R Jr | Amelioration or elimination of postoperative pain |
US4938970A (en) * | 1987-02-06 | 1990-07-03 | Hustead Robert E | Painless electrolyte solutions |
JPH01135721A (ja) * | 1987-10-29 | 1989-05-29 | Geneco Inc | 腹腔内感染を除去するための方法及び溶液 |
CA1341093C (en) * | 1988-05-31 | 2000-09-05 | Eugene P. Goldberg | Method and composition for preventing surgical adhesions |
USH1139H (en) * | 1988-07-21 | 1993-02-02 | E. R. Squibb & Sons, Inc. | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination |
US5304724A (en) * | 1988-09-09 | 1994-04-19 | Entravision, Inc. | Tissue irrigating solution |
US5051443A (en) * | 1988-10-12 | 1991-09-24 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
US5036046A (en) * | 1988-10-12 | 1991-07-30 | Eye Research Institute Of Retina Foundation, Inc. | Method for enhancing healing of corneal endothelial wounds |
US4920227A (en) * | 1988-11-29 | 1990-04-24 | Rorer Pharmaceutical Corp. | Benzobicyclic carboxamide 5-HT3 antagonists |
US5116615A (en) * | 1989-01-27 | 1992-05-26 | Immunolytics, Inc. | Method for treating benign prostatic hypertrophy |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
GB8929076D0 (en) * | 1989-12-22 | 1990-02-28 | Scras | Treatment of shock by blocking agents of edrf effect or formation |
EP0502143B1 (en) * | 1990-09-07 | 1995-11-08 | Universidad De Alicante | Composition for treating ocular pain |
GB9022250D0 (en) * | 1990-10-12 | 1990-11-28 | Glaxo Group Ltd | Medicaments |
ATE118168T1 (de) * | 1990-12-03 | 1995-02-15 | Vestar Inc | Verhütung der synovialischen adhäsion. |
JP2520895Y2 (ja) * | 1990-12-28 | 1996-12-18 | 曙ブレーキ工業株式会社 | ディスクブレーキの圧油導入部 |
US5250519A (en) * | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
CA2106762C (en) * | 1991-04-19 | 2000-10-10 | Donald J. Kyle | Bradykinin antagonist peptides |
US5350761A (en) * | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
DK0533280T4 (da) * | 1991-09-20 | 2005-02-28 | Glaxo Group Ltd | Ny medicinsk anvendelse af tachykininantagonister |
DE4135157C2 (de) * | 1991-10-24 | 1995-06-14 | Luitpold Pharma Gmbh | Verwendung wäßriger Kohlenhydrat-Lösungen als Spülflüssigkeit für die Arthroskopie |
GB9216155D0 (en) * | 1992-07-30 | 1992-09-09 | Geistlich Soehne Ag | Treatment of dentoalveolar infections |
US5525357A (en) * | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5650447A (en) * | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
US5521158A (en) * | 1992-10-08 | 1996-05-28 | Scios Nova Inc. | Pseudopeptide bradykinin receptor antagonists |
AU5405894A (en) * | 1992-10-21 | 1994-05-09 | Alcon Laboratories, Inc. | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery |
US5620687A (en) * | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
JPH09506620A (ja) * | 1993-12-17 | 1997-06-30 | アルコン・ラボラトリーズ,インコーポレイテッド | 非ステロイド抗炎症剤を含有する改良された眼内洗浄溶液 |
US5482925A (en) * | 1994-03-17 | 1996-01-09 | Comedicus Incorporated | Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents |
IE940292A1 (en) * | 1994-04-06 | 1995-10-18 | Elan Corp Plc | Biodegradable microcapsules and method for their manufacture |
US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
US5576317A (en) * | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
BR9509985A (pt) * | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solução para irrigação e método para inibição de dor inflamação e esparmo |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
WO2004031143A2 (en) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
US7358091B2 (en) * | 2004-12-14 | 2008-04-15 | Portola Pharmaceuticals, Inc. | Device and methods for identifying and treating aspirin non-responsive patients |
-
1995
- 1995-12-12 EP EP10182117.1A patent/EP2301562B1/en not_active Expired - Lifetime
- 1995-12-12 EP EP05076510A patent/EP1609477B1/en not_active Expired - Lifetime
- 1995-12-12 ES ES10182117T patent/ES2421306T3/es not_active Expired - Lifetime
- 1995-12-12 RU RU97112158/14A patent/RU2180852C2/ru active
- 1995-12-12 WO PCT/US1995/016028 patent/WO1996019233A2/en active IP Right Grant
- 1995-12-12 MX MX9703988A patent/MX9703988A/es active IP Right Grant
- 1995-12-12 ES ES95943396T patent/ES2244966T3/es not_active Expired - Lifetime
- 1995-12-12 AT AT95943396T patent/ATE300308T1/de not_active IP Right Cessation
- 1995-12-12 ES ES05076510T patent/ES2377126T3/es not_active Expired - Lifetime
- 1995-12-12 CA CA002206119A patent/CA2206119C/en not_active Expired - Lifetime
- 1995-12-12 EP EP95943396A patent/EP0799051B1/en not_active Expired - Lifetime
- 1995-12-12 AT AT05076510T patent/ATE532530T1/de active
- 1995-12-12 DE DE69534341T patent/DE69534341T2/de not_active Expired - Lifetime
- 1995-12-12 CN CNB951975382A patent/CN1160115C/zh not_active Expired - Lifetime
-
1996
- 1996-06-26 US US08/670,706 patent/US5860950A/en not_active Expired - Lifetime
- 1996-06-26 US US08/673,171 patent/US5858017A/en not_active Expired - Lifetime
- 1996-06-26 US US08/670,703 patent/US5800385A/en not_active Expired - Lifetime
-
1998
- 1998-08-07 HK HK98109777A patent/HK1008983A1/xx not_active IP Right Cessation
-
2005
- 2005-11-17 NO NO20055445A patent/NO20055445L/no not_active Application Discontinuation
-
2006
- 2006-11-09 JP JP2006304621A patent/JP2007031454A/ja not_active Withdrawn
-
2007
- 2007-08-03 US US11/890,273 patent/US20080096948A1/en not_active Abandoned
- 2007-09-06 US US11/899,623 patent/US20080114025A1/en not_active Abandoned
- 2007-12-14 US US12/002,227 patent/US20080167388A1/en not_active Abandoned
-
2008
- 2008-09-08 JP JP2008230339A patent/JP2009024022A/ja not_active Withdrawn
-
2012
- 2012-07-06 JP JP2012152853A patent/JP2012184274A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1008983A1 (en) | 1999-07-23 |
MX9703988A (es) | 1998-02-28 |
JP2009024022A (ja) | 2009-02-05 |
US20080096948A1 (en) | 2008-04-24 |
US20080167388A1 (en) | 2008-07-10 |
EP0799051A2 (en) | 1997-10-08 |
DE69534341D1 (de) | 2005-09-01 |
RU2180852C2 (ru) | 2002-03-27 |
EP2301562A1 (en) | 2011-03-30 |
ATE532530T1 (de) | 2011-11-15 |
WO1996019233A2 (en) | 1996-06-27 |
US5860950A (en) | 1999-01-19 |
ATE300308T1 (de) | 2005-08-15 |
US20080114025A1 (en) | 2008-05-15 |
US5800385A (en) | 1998-09-01 |
JP2012184274A (ja) | 2012-09-27 |
EP0799051B1 (en) | 2005-07-27 |
JP2007031454A (ja) | 2007-02-08 |
ES2377126T3 (es) | 2012-03-22 |
ES2421306T3 (es) | 2013-08-30 |
CN1160115C (zh) | 2004-08-04 |
WO1996019233A3 (en) | 1996-09-19 |
EP1609477A1 (en) | 2005-12-28 |
EP2301562B1 (en) | 2013-04-17 |
DE69534341T2 (de) | 2006-05-24 |
CN1175213A (zh) | 1998-03-04 |
CA2206119C (en) | 2008-05-13 |
ES2244966T3 (es) | 2005-12-16 |
US5858017A (en) | 1999-01-12 |
CA2206119A1 (en) | 1996-06-27 |
EP1609477B1 (en) | 2011-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055445L (no) | Anvendelse av en blanding for fremstilling av et medikament for perioperativt a hemme smerte, betennelse og/eller spasme, og en losning for perioperativt a hemme smerte, betennelse og/eller spasme | |
Nishida et al. | Tranexamic acid and trauma-induced coagulopathy | |
Calogiuri et al. | Chlorhexidine hypersensitivity: a critical and updated review | |
JP2008094855A (ja) | 疼痛、炎症、けいれんおよび再狭窄の抑制のための血管灌注溶液並びにその方法 | |
Curto et al. | Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran | |
Dogra et al. | What's new in cicatricial alopecia? | |
Miesbach et al. | Von W illebrand disease–the ‘D os’ and ‘D on'ts’ in surgery | |
CA2143416C (en) | Inhibitor of collagen-stimulated platelet aggregation | |
BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
EP0744952A1 (en) | Method for treating vascular obstructions caused by abnormal cells | |
Antevil et al. | Intraoperative anaphylactic shock associated with bacitracin irrigation during revision total knee arthroplasty: a case report | |
Ramsook et al. | Timing of platelet rich plasma injections during antithrombotic therapy | |
Nielsen et al. | ε-Aminocaproic acid inhibition of fibrinolysis in vitro: should the ‘therapeutic’concentration be reconsidered? | |
WO2000023062A3 (en) | Irrigation solution and method for inhibition of pain and inflammation | |
JPH02288826A (ja) | 抗腫瘍活性物質を有する皮膚治療薬 | |
SOBHIA et al. | The role of platelet rich plasma in comparison with corticosteroids in the treatment of De Quervain tenosynovitis | |
US5631246A (en) | Use of PAF | |
Kwa et al. | Using fibrin sealant for skin graft fixation to avoid sedation in children with burns: a prospective study | |
AU1345000A (en) | Irrigation solution and method for inhibition of pain and inflammation | |
Strandberg et al. | Anticoagulant effects of low-molecular-weight heparin following thrombolytic therapy in acute myocardial infarction: a dose-finding study | |
BR9916733A (pt) | Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm | |
Kaye et al. | Pharmacokinetic study of oral ε-aminocaproic acid in the northern elephant seal (Mirounga angustirostris) | |
Wilson et al. | Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty | |
WO2000023061A3 (en) | Irrigation solution and method for inhibition of pain and inflammation | |
Colman et al. | High molecular weight kininogen, the extracellular inhibitor of thiol proteases, is deficient in hamsters with muscular dystrophy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
FC2A | Withdrawal, rejection or dismissal of laid open patent application |